Program Description: 


Tamam Bakchoul "Clinical Manifestations"

This presentation will highlight the pathophysiology of HIT, emphasizing characteristic clinical features. In addition, a summary of current therapeutic options for patients with HIT will be provided.

Ismail Elalamy "Laboratory Measurement"

HIT diagnosis remains a clinical challenge. There is no gold standard or certainty criteria so practitioners have to establish HIT diagnosis based on greater imputability. In fact, practitioners have to reinforce the probability of this etiology to be convinced and secure optimally the patient journey.

HIT diagnosis is prospectively built on both functional and immunological assays. The recent technical progress allowed new tests more rapid, more accurate, more simple, more accessible but their use must be well understood and well combined to improve HIT management. This presentation will review the advantages and limits of all these assays to draw the best way of HIT diagnosis in 2016: practical, useful and reliable. 

Moderator: Ketan Kulkarni


Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
More information and online registration: 

This meeting is being supported by Instrumentation Laboratory

Target audience: 
  • All doctors and scientists using heparin
  • Physicians heparin prescribers
  • Anesthesiologists suspecting HIT
  • Biologists detecting HIT
  • Students learning HIT
Learning objectives: 

At the end of this Webinar, the participants will be able to:

  • Establish differential diagnosis for acquired thrombocytopenia              
  • Select appropriate upfront management of heparin-induced thrombocytopenia (HIT)
  • Discuss treatment options for patients who are suspected to have HIT
  • Know all the assays characteristics : limits and advantages
  • Identify the best sequence for their potential combination
  • Define a well-informed diagnosis strategy
  • See right and do right to decide right
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
Yukio Ozaki

Tamam Bakchoul "Clinical Manifestations"

Ismail Elalamy "Laboratory Measurement"


Moderator: Ketan Kulkarni, IWK Health Centre (Canada)


All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  





Geoffrey Barnes, MDPortolaConsulting
 Blue Cross Blue Shield of MichiganResearch
Chris Ward, PhDBayerSpeaker
 Boehringer-IngelheimSpeaker, Advisory Board
 BMS/PfizerSpeaker, Advisory Board
Yukio OzakiThe Sysmex CorporationAdvisory Board

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved






Lacey Schmeidler, MA
Phone number: 
+1 (919) 929-3807
Session date: 
09/07/2016 - 7:00am to 8:00am CDT
ISTH Webinar Library Once a Month
Carrboro, NC 27510
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.